Processa Pharmaceuticals Inc (PCSA)
2.48
0.00 (0.00%)
USD |
NASDAQ |
May 08, 16:00
2.475
0.00 (0.00%)
After-Hours: 20:00
Processa Pharmaceuticals Enterprise Value: 2.405M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 07, 2024 | 2.405M |
May 06, 2024 | 2.005M |
May 03, 2024 | 1.491M |
May 02, 2024 | 1.748M |
May 01, 2024 | 1.634M |
April 30, 2024 | 1.520M |
April 29, 2024 | 1.291M |
April 26, 2024 | 1.434M |
April 25, 2024 | 2.234M |
April 24, 2024 | -0.0795M |
April 23, 2024 | -0.1366M |
April 22, 2024 | -0.3365M |
April 19, 2024 | -0.1937M |
April 18, 2024 | -0.2508M |
April 17, 2024 | 0.0348M |
April 16, 2024 | -0.308M |
April 15, 2024 | -0.3794M |
April 12, 2024 | 0.0633M |
April 11, 2024 | 0.3204M |
April 10, 2024 | 0.5488M |
April 09, 2024 | 3.605M |
April 08, 2024 | 3.819M |
April 05, 2024 | 3.262M |
April 04, 2024 | 1.920M |
April 03, 2024 | 2.034M |
Date | Value |
---|---|
April 02, 2024 | 2.548M |
April 01, 2024 | 2.005M |
March 28, 2024 | 2.048M |
March 27, 2024 | 1.777M |
March 26, 2024 | 1.491M |
March 25, 2024 | 1.720M |
March 22, 2024 | 1.691M |
March 21, 2024 | 1.491M |
March 20, 2024 | -0.898M |
March 19, 2024 | -0.8468M |
March 18, 2024 | -0.7956M |
March 15, 2024 | -0.9663M |
March 14, 2024 | -0.898M |
March 13, 2024 | -0.7956M |
March 12, 2024 | -0.8297M |
March 11, 2024 | -0.8126M |
March 08, 2024 | -0.8297M |
March 07, 2024 | -0.7614M |
March 06, 2024 | -0.7443M |
March 05, 2024 | -0.8126M |
March 04, 2024 | -0.4199M |
March 01, 2024 | -0.5053M |
February 29, 2024 | -0.5053M |
February 28, 2024 | -0.676M |
February 27, 2024 | -0.7443M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-2.661M
Minimum
Sep 28 2023
188.70M
Maximum
Mar 18 2021
41.09M
Average
31.06M
Median
Jun 22 2022
Enterprise Value Benchmarks
DIH Holding US Inc | -- |
NovaBay Pharmaceuticals Inc | 2.560M |
Palatin Technologies Inc | 24.08M |
iBio Inc | 16.84M |
Theriva Biologics Inc | -13.05M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -2.405M |
Total Expenses (Quarterly) | 2.470M |
EPS Diluted (Quarterly) | -1.68 |
Earnings Yield | -358.8% |
Normalized Earnings Yield | -5697.72 |